Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD). "Dry AMD is driven by a number of factors that contribute to the death of retinal ...

Analysts anticipate Lineage Cell Therapeutics to report an earnings per share (EPS) of $-0.03. Anticipation surrounds Lineage ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 6.64%, which has investors questioning if this is right time to buy.

Cognition Therapeutics (CGTX) reported preclinical data this week at the Association for Research in Vision and Ophthalmology showing the ...

Boehringer Ingelheim has started a proof-of-concept trial of a drug that could offer the first oral treatment for geographic ...

Ocular complications in Thalassemia Major are often overlooked, yet early detection through regular eye exams is vital for ...

Researchers presented an exploratory analysis comparing OCT biomarkers in a Phase 1b study of ONL1204 in patients with ...